Project Grant R01HL180429
Award Date 8/15/25
Completion Date 5/31/29
Dollars Obligated $736K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), awarded a $699,133 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The project aims to investigate the molecular insights into the actions of SGLT2 inhibitors and GLP1 agonists across the heart,...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
- The University of Arizona was awarded a $735,838 project grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on July 15, 2025. The grant supports research into the role of hexokinase 1 (HK1) mitochondrial dislocation in the development of heart failure with preserved ejection fraction (HFpEF). The key objectives are to investigate how HK1 dislocation leads to increased protein O-GlcNAcylation in cardiac endothelial cells, and to assess...
- This federal Project Grant award of $650,028, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project at the University of California, Los Angeles (UCLA) to investigate the role of phosphodiesterases in regulating cyclic AMP signaling, excitation-contraction coupling, and arrhythmias in heart failure. The key objectives are to determine the differential effects of phosphodiesterase 4D signaling on cardiac...
- The federal Project Grant award of $126,387.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at The Johns Hopkins University to investigate the role of reduced hypusination of the translation factor eIF5A in the development of heart failure with preserved ejection fraction (HFpEF). The key objectives are to test the hypothesis that decreased eIF5A hypusination impairs the translation of ubiquitin precursors and...
- This federal Project Grant award of $169,020.00 was provided by the National Heart Lung and Blood Institute (NHLBI), which operates under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pennsylvania investigating the impact of obesity and diabetes on coronary microvascular defects in heart failure with preserved ejection fraction (HFpEF). The research will use an animal model of HFpEF to compare the temporal progression...
- This federal Project Grant award of $231,552.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Northwestern University supports research on the role of the MTCH2 gene in cardiac regulation, heart failure, and obesity. The key objectives are to investigate how reduced MTCH2 protein affects mitochondrial function and dynamics in the heart, potentially leading to cardiomyopathy and weight loss. The research involves creating a...
- The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
- This Project Grant award of $576,786.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at the University of Arizona to investigate the role of the YTHD2 protein in regulating the translation of the NRF2 protein under conditions of oxidative stress. The research aims to elucidate the mechanisms by which certain proteins, like NRF2, can continue to be translated despite the general inhibition of protein...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to discover novel biomarkers and biological mechanisms underlying early-stage heart failure (HF). The $147,486 award to Duke University will support the development of an automated computational phenotype to identify early-stage HF, which will then be applied to large population cohorts. The research aims to leverage multi-omics data integration and...